The insulin-like growth factor system: Basic and clinical aspects

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 3, 1999, Pages 355-361

  Bach, L A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR;

AGING; AVASCULAR NECROSIS; BELL PALSY; CANCER RISK; DIABETES MELLITUS; DOPING; DRUG MECHANISM; DRUG RECEPTOR BINDING; EDEMA; FACE PAIN; FEMUR HEAD NECROSIS; GROWTH REGULATION; GYNECOMASTIA; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC DISORDER; METABOLISM; PAROTID GLAND DISEASE; REVIEW; SHORT STATURE; WOUND HEALING;

EID: 0033062322     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb00719.x     Document Type: Review

References (37)

1. 1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
2. 2. Guler H-P, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987; 317: 137-40.
3. 3. Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995; 3: 38-61.
4. 4. Baxter RC, Martin JL. Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: Determination by reconstitution and affinity-labelling. Proc Natl Acad Sci USA 1989; 86: 6898-902.
5. 5. Kim HS, Nagalla SR, Oh Y, Wilson E, Roberts CT, Rosenfeld RG. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs) -characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci USA 1997; 94: 12981-6.
6. 6. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 1990; 70: 1292-8.
7. 7. Botfield C, Ross RJM, Hinds CJ. The role of IGFs in catabolism. Bailliere's Clin Endocrinol Metab 1997; 11: 679-97.
8. 8. Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes/Metab Rev 1992; 8: 229-57.
9. 9. de Souza AT, Yamada T, Mills JJ, Jirtle RL. Imprinted genes in liver carcinogenesis. FASEB J 1997; 11: 60-7.
10. 10. Weksberg R, Shen DR, Fei YL, Song QL, Squire J. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nature Genet 1993; 5: 143-50.
11. 11. Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol 1996; 149: 367-72.
12. 12. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55: 249-52.
13. 13. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730-4.
14. 14. Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone G, Marino V et al. Prostatic hyperplasia - an unknown feature of acromegaly. J Clin Endocrinol Metab 1998; 83: 775-9.
15. 15. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P et al. Plasma insulin-like growth factor I and prostate cancer risk - a prospective study. Science 1998; 279: 563-6.
16. 16. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-6.
17. 17. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Med 1997; 3: 1141-4.
18. 18. Helle SI, Geisler J, Poulsen JP, Hestdal K, Meadows K, Collins W et al. Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer - a phase I study. Br J Cancer 1998; 78: 14-20.
19. 19. Baxter RC. The role of insulin-like growth factors and their binding proteins in tumour hypoglycemia. Horm Res 1996; 46: 195-201.
20. 20. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 1991; 34: 675-9.
21. 21. Le Roith D. Insulin-like growth factors. N Engl J Med 1997; 336: 633-40.
22. 22. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199-204.
23. 23. Mitchell P, Higo H, Duan C, Clemmons DR, Herman B. Cancelled IGF-I trials bode ill for diabetic patients. Lancet 1997; 350: 1606.
24. 24. Moller N, Orskov H. Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications? Lancet 1997; 350: 1188-9.
25. 25. Ishii DN. Implications of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Rev 1995; 20: 47-67.
26. 26. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-33.
27. 27. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993; 91: 391-6.
28. 28. Hammerman MR, Miller SB. Effects of growth hormone and insulin-like growth factor I on renal growth and function. J Pediatr 1997; 131: S17-19.
29. 29. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-14.
30. 30. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-7.
31. 31. Sacca L. Growth hormone: a newcomer in cardiovascular medicine. Cardiovasc Res 1997; 36: 3-9.
32. 32. Adams S, Rosen D, Sommer A. rhIGF-I/IGFBP-3 (SomatoKine) therapy for the treatment of osteoporosis. In: Takano K, Hizuka N, Takahashi SI (Eds). Molecular mechanisms to regulate the activities of insulin-like growth factors. Amsterdam: Elsevier, 1998: 327-30.
33. 33. Dore S, Kar S, Quirion R. Rediscovering an old friend, IGF-I - potential use in the treatment of neurodegenerative diseases. Trends Neurosci 1997; 20: 326-31.
34. 34. Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 1996; 17: 423-80.
35. 35. Franklin SC, Moulton M, Sicard GA, Hammerman MR, Miller SB. Insulin-like growth factor I preserves renal function postoperatively. Am J Physiol 1997; 41: F257-259.
36. 36. Kicman AT, Miell JP, Teale JD, Powrie J, Wood PJ, Laidler P et al. Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH. Clin Endocrinol 1997; 47: 43-50.
37. 37. Wallace JD, Cuneo RC, Baxter RC, Rosen T, Ba B, Dall R et al. Endocrine markers of growth hormone abuse in sport. Proc Endocrine Soc Aust 1998; 41: 55 (Abstr.).